Sydney, Australia: The administration of cannabidiol (CBD) is associated with reduced cravings for methamphetamine in rats, according to preclinical data published in the Journal of Psychopharmacology.
Australian researchers assessed the impact of CBD on methamphetamine-seeking behavior in a rat model. They reported that CBD dosing reduced the animals’ motivation to self-administer methamphetamine and reduced the likelihood of relapse following drug abstinence.
Authors concluded, "This is the first demonstration that cannabidiol can reduce the motivation to seek and consume methamphetamine, and suggests that cannabidiol might be worth trialing as a novel pharmacotherapy for methamphetamine dependence."
Prior studies have similarly reported that CBD is associated with reduced cravings for tobacco, heroin, cocaine, and opioids.
For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, "Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats," appears in the Journal of Psychopharmacology.